Tg Therapeutics (TGTX) Stock Price, Quote & News

Company Profile

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The com...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 554 4484

Fax: 212 554 4531

Website: www.tgtherapeutics.com

Address:

3020 Carrington Mill Blvd., Suite 475, Morrisville, United States

inv1ncible Apr. 19 at 10:12 PM

$TGTX https://www.marketscreener.com/news/eli-lilly-in-advanced-talks-to-acquire-kelonia-therapeutics-for-over-2-billion-wsj-says-ce7e50d3dc8ff723 Waiting for our turn

0 · Reply

Wolves1 Apr. 19 at 7:05 PM

$TGTX Interesting 🤔

0 · Reply

financiern Apr. 19 at 11:48 AM

$TGTX love when bears become bulls and admit we were right all along https://seekingalpha.com/article/4891828-tg-therapeutics-flawless-execution-and-500m-non-dilutive-capital-bolster-outlook?share_source=shared_news

1 · Reply

Wolves1 Apr. 19 at 8:29 AM

$TGTX You see l've been through the desert. On a horse with no name. In the desert ..... you can remember your name. Cause their ain't no one for to give you no pain .... 😝😝😝😝😝😝😝😝

0 · Reply

Quad_ Apr. 18 at 4:25 PM

$TGTX The buyout is stuck in the Strait of Hormuz. That is my guess.

1 · Reply

Looey Apr. 18 at 3:45 PM

$TGTX first quarter Conference Call in 2025 was on May 5. So we have 2 weeks. Hopefully we get some color on early sub q results and early Azer cell results. 🤞

1 · Reply

DragonAlgo Apr. 18 at 3:30 AM

🐉 $TGTX CALL — DragonAlgo® Signal Contract: TGTX CALL Expiry: 2026-05-15 | Strike: $39.00 | Type: CALL Option Plan (premium): Entry: $0.95 Stop: $0.68 TP1: $1.23 TP2: $1.61 TP3: $2.28 🔗 https://dragonalgo.com

0 · Reply

ChartistMoM Apr. 18 at 3:24 AM

$TGTX Where is my son!

3 · Reply

Lions1_83 Apr. 18 at 12:22 AM

$TGTX Another beautiful day in TGTX land. Let's continue the climb on Monday . Have a good weekend all GLTA💰

0 · Reply

CrollSprings Apr. 17 at 8:34 PM

$CADL $SLS $IBRX and my lagard $TGTX Good day, beers on me !

1 · Reply

TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI

Mar 19, 2026, 7:30 AM EDT - 4 weeks ago

TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million

Mar 9, 2026, 7:30 AM EDT - 5 weeks ago

Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis

Mar 6, 2026, 7:30 AM EST - 6 weeks ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

Mar 2, 2026, 7:01 AM EST - 6 weeks ago

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

DTIL

Feb 26, 2026, 7:00 AM EST - 7 weeks ago

TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Feb 23, 2026, 7:30 AM EST - 7 weeks ago

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update

Feb 8, 2026, 4:17 PM EST - 2 months ago

TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis

Feb 6, 2026, 7:30 AM EST - 2 months ago

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Jan 15, 2026, 10:31 AM EST - 3 months ago

These under-the-radar stocks combine fast growth with big upside potential

AGYS ASTH BBT CORT CTRE DCOM DOCN

Jan 13, 2026, 5:05 PM EST - 3 months ago

TG Therapeutics Stock Climbs After The Bell: Here's Why

Jan 7, 2026, 7:30 AM EST - 3 months ago

TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Nov 28, 2025, 7:30 AM EST - 5 months ago

TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Oct 31, 2025, 7:30 AM EDT - 6 months ago

TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update

Oct 28, 2025, 7:30 AM EDT - 6 months ago

TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI

Sep 24, 2025, 9:10 AM EDT - 7 months ago

New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

Sep 10, 2025, 7:30 AM EDT - 7 months ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Sep 8, 2025, 7:30 AM EDT - 7 months ago

TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment

Sep 4, 2025, 7:30 AM EDT - 8 months ago

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:30 AM EDT - 8 months ago

TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program

Aug 28, 2025, 8:00 AM EDT - 8 months ago

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

Aug 4, 2025, 7:00 AM EDT - 9 months ago

TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Jul 30, 2025, 7:30 AM EDT - 9 months ago

TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update

Jun 9, 2025, 4:51 PM EDT - 11 months ago

Evercore ISI's Julian Emanuel says now is the time to buy small-caps

CNS LEU RMBS SFM

Jun 6, 2025, 7:30 AM EDT - 11 months ago

TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 27, 2025, 7:30 AM EDT - 11 months ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

May 5, 2025, 4:37 PM EDT - 1 year ago

TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show

May 5, 2025, 7:00 AM EDT - 1 year ago

TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

Apr 30, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

Apr 10, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

Apr 7, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

Mar 21, 2025, 11:50 AM EDT - 1 year ago

Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher

Mar 7, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

Mar 4, 2025, 7:03 AM EST - 1 year ago

Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025

CORT GILD PRVA TKO

Feb 27, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Feb 26, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update

Feb 18, 2025, 10:20 AM EST - 1 year ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

ARWR AUB CRK CYTK EXE KRYS MARA

Jan 9, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 7:36 AM EST - 1 year ago

20 stocks likely to lag the S&P 500 over the next year — for this one reason

CELH CENX CNXC CRSR CXM FLG GEO

Nov 29, 2024, 8:00 AM EST - 1 year ago

TG Therapeutics to Participate in the Evercore HealthCONx Conference

Nov 21, 2024, 6:00 AM EST - 1 year ago

TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Nov 4, 2024, 9:00 AM EST - 1 year ago

FUJIFILM Diosynth Biotechnologies Signs Manufacturing Supply Agreement with TG Therapeutics

Nov 1, 2024, 8:06 AM EDT - 1 year ago

TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update

Sep 18, 2024, 7:15 AM EDT - 1 year ago

New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis

Sep 18, 2024, 7:00 AM EDT - 1 year ago

New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment

Sep 5, 2024, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Aug 6, 2024, 9:01 AM EDT - 1 year ago

HealthCare Royalty and Blue Owl Announce $250M Debt Financing with TG Therapeutics

Aug 5, 2024, 7:30 AM EDT - 1 year ago

TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update

Jun 7, 2024, 7:50 AM EDT - 2 years ago

TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 3, 2024, 7:30 AM EDT - 2 years ago

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

inv1ncible Apr. 19 at 10:12 PM

$TGTX https://www.marketscreener.com/news/eli-lilly-in-advanced-talks-to-acquire-kelonia-therapeutics-for-over-2-billion-wsj-says-ce7e50d3dc8ff723 Waiting for our turn

0 · Reply

Wolves1 Apr. 19 at 7:05 PM

$TGTX Interesting 🤔

0 · Reply

financiern Apr. 19 at 11:48 AM

1 · Reply

Wolves1 Apr. 19 at 8:29 AM

0 · Reply

Quad_ Apr. 18 at 4:25 PM

$TGTX The buyout is stuck in the Strait of Hormuz. That is my guess.

1 · Reply

Looey Apr. 18 at 3:45 PM

$TGTX first quarter Conference Call in 2025 was on May 5. So we have 2 weeks. Hopefully we get some color on early sub q results and early Azer cell results. 🤞

1 · Reply

DragonAlgo Apr. 18 at 3:30 AM

0 · Reply

ChartistMoM Apr. 18 at 3:24 AM

$TGTX Where is my son!

3 · Reply

Lions1_83 Apr. 18 at 12:22 AM

$TGTX Another beautiful day in TGTX land. Let's continue the climb on Monday . Have a good weekend all GLTA💰

0 · Reply

CrollSprings Apr. 17 at 8:34 PM

$CADL $SLS $IBRX and my lagard $TGTX Good day, beers on me !

1 · Reply

financiern Apr. 17 at 7:07 PM

$TGTX not bad volume either. Granted it’s opex, but still.

0 · Reply

financiern Apr. 17 at 7:05 PM

$TGTX if you wanna close at the HOD I won’t be upset.

0 · Reply

grk2025 Apr. 17 at 6:43 PM

$TGTX I feel this time we are going to test 55

4 · Reply

CedarPark Apr. 17 at 6:38 PM

$TGTX I want 36

1 · Reply

CedarPark Apr. 17 at 6:36 PM

$TGTX outperforming the XBI today, I like it. Hopefully we are allowed to close over $35 by the options gods. BUY.

0 · Reply

Wolves1 Apr. 17 at 6:16 PM

$TGTX 🏹

0 · Reply

grk2025 Apr. 17 at 5:46 PM

$TGTX 🥇🚀

1 · Reply

CT_Biker Apr. 17 at 5:41 PM

$TGTX sold a few more JAN 60 calls. They’re getting scooped up. Gonna wait until after ER to do anything else.

1 · Reply

Auphiliate Apr. 17 at 5:09 PM

$TGTX Really liking what I see here! 😊

0 · Reply

investor757 Apr. 17 at 5:03 PM

$TGTX Nice day so far. Let’s blow through that HOD! Wife’s next round of Briumvi treatment is next Wednesday. Since the first two rounds were so great, she has zero worries, and is excited for them. The last 6 months she’s felt incredible.

4 · Reply

Rutgers Apr. 17 at 5:01 PM

$TGTX Hey, anybody heard from SHARTIST lately? Curious his thoughts? I’m actually hoping for a short drop to get a little more bulled up!! 30k shares and want to add prior to the earnings! need a Shartist to shed some light on a pullback?

4 · Reply

jmartin795 Apr. 17 at 4:34 PM

$TGTX

0 · Reply

Market Cap	5.64B
Revenue (ttm)	616.29M
Net Income (ttm)	447.18M
EPS (ttm)	N/A
PE Ratio	12.38
Forward PE	24.65
Profit Margin	72.56%
Debt to Equity Ratio	0.38

Volume	2,607,400
Avg Vol	1,896,156
Day's Range	N/A - N/A
Shares Out	159.69M
Stochastic %K	89%
Beta	1.76
Analysts	Strong Sell
Price Target	$44.43